ArticlePeerJ2026
PLK1 overexpression as a dual-role biomarker and therapeutic vulnerability in pulmonary adenocarcinoma.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PLK1 is associated with various malignant tumors, but its correlation with lung adenocarcinoma (LUAD) remains unclear. This research seeks to explore the differences in PLK1 expression in LUAD and evaluate the relationship between PLK1 expression and the outcomes for LUAD patients. Methods: Information on LUAD patients was sourced from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx). The XianTao Academic Online Platform was employed for systematic analysis of PLK1, including: (1) Wilcoxon rank-sum test to compare PLK1 expression between LUAD and normal tissues; (2) logistic regression analysis evaluating PLK1-clinicopathological feature relationships; (3) Kaplan-Meier and COX regression analyses assessing prognostic significance; (4) nomogram construction for survival prediction. Immunohistochemical (IHC) staining results from the Human Protein Atlas (HPA) validated PLK1 protein expression. Functional characterization using the XianTao platform included: (1) Analysis of PLK1-coexpressed genes using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways; (2) single-sample gene set enrichment analysis (ssGSEA) to measure immune cell infiltration in tumors with high PLK1 expression. Results: PLK1 expression was significantly elevated in LUAD tumor tissues compared to adjacent normal samples across multiple cohorts. Elevated PLK1 expression was strongly associated with advanced clinicopathological stages (tumor/node/metastasis (T/N/M)) and poorer overall survival. Functional enrichment analysis revealed that genes co-expressed with PLK1 were predominantly involved in cell cycle regulatory pathways. Furthermore, transcriptomic profiling indicated a significant correlation between high PLK1 expression and an immunosuppressive tumor microenvironment. Experimental validation in A549 cells demonstrated that pharmacological inhibition of PLK1 ( Conclusion: PLK1 overexpression signifies aggressive disease and poor prognosis in LUAD, mechanistically linked to cell cycle dysregulation and an immunosuppressive microenvironment. Our findings nominate PLK1 as a promising therapeutic target and biomarker, warranting further investigation into PLK1-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.